Arizona Tribune - Moolec Science Scales GLASO U.S. Platform With Record 2025 Campaign and Expansion Into Nutrition & Supplements Market

The 2025 campaign marks a major operational milestone, demonstrating that Moolec can deliver consistent performance at significantly increased acreage, transitioning from prior development and smaller-scale campaigns into successful large-scale agricultural execution.

2025 GLASO¹ Campaign Highlights

• 1,100 acres dedicated for safflower production across the United States

• Average yield of approximately 2,200 lb/acre, up from 1,400 lb/acre in 2024, representing a 57.1% year-over-year increase

• Harvest performance materially exceeded internal forecasts, reinforcing confidence in agronomic optimization and operational execution

Large-Scale Validation Across the Value Chain

With acreage expanded by more than 100% relative to previous cycles, the 2025 campaign provided the first demonstration that GLASO¹ can operate successfully at commercial scale, encompassing expanded field deployment and large-volume harvest management.

These results confirm Moolec's ability to translate its plant-engineered molecular farming platform from controlled deployments into large-scale agricultural operations, using existing farming infrastructure while maintaining traceability, quality, and cost discipline.

High-Growth Commercial Opportunity in Nutrition & Supplements

Moolec's planned entry into the nutrition and supplements market is supported by early demand from leading wellness and performance brands in the United States. These organizations operate at the intersection of metabolic health, personalized nutrition, and elite fitness, sectors characterized by strong growth, premium pricing, and stringent purity requirements.

Interest from these companies, each serving large, engaged consumer communities, provides Moolec with:

• Immediate access to high-value, recurring demand pools

• A market that prioritizes clean-label, traceable, plant-engineered functional lipids

• A commercial environment where high-concentration GLA offers differentiated formulation advantages

This early market pull positions GLASO¹ to enter one of the most dynamic segments of the nutrition industry.

Planned Expansion Into High-Concentration GLA Softgel Applications

Building on the success of the 2025 campaign, Moolec intends to expand into softgel nutritional applications with a high-concentration GLA formulation derived from its engineered safflower platform.

This planned expansion is expected to:

• Unlock higher value-added commercialization pathways

• Provide access to established global softgel distribution channels

• Differentiate GLASO¹ through concentration, purity, and plant-engineered origin

Execution-Led Growth Strategy

"The 2025 campaign represents a defining moment for GLASO¹," said Alejandro Antalich, CEO at Moolec Science. "Scaling acreage by more than 100% while strengthening performance shows the maturity of our plant-engineered platform. The interest we are receiving from influential wellness and performance brands signals a broader shift toward scientifically engineered functional lipids. With this year's success, GLASO¹ is equipped to move into higher-value formats such as concentrated softgels, unlocking a new phase of growth."

Focus on Fundamentals

Moolec continues to prioritize:

• Scaling validated platforms with discipline

• Capital-efficient growth aligned with demonstrated performance

• Transparent, execution-driven communication with shareholders

The Company views the 2025 GLASO¹ campaign as a foundational step toward repeatable commercial-scale production and accelerated entry into high-value nutritional markets.

¹ Pat. US11/438,951 and US13/025,345

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Moolec Science's Contacts:

Investor Relations inquiries: [email protected]

SOURCE: Moolec Science

View the original press release on ACCESS Newswire

E.Rodriguez--AT